Alzheimer’s Drug Development: Not An Easy Path To Pursue
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
